---
id: sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026
kind: topic
title: "HSA Post-marketing Vigilance Guidance 2026"
url: https://ik.sg/en/knowledge/topic/sgtopic.healthcare.hsa-post-marketing-vigilance-guidance-2026
language: en
evidence_status: recorded
collection_as_of: 2026-11-22
---

# HSA Post-marketing Vigilance Guidance 2026

HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.

## Record details

- **Also known as:** HSA post-marketing vigilance; therapeutic product adverse-event reporting Singapore; CTGTP vigilance guidance
- **Evidence profile:** mixed
- **Description:** HSA’s 2026 post-marketing vigilance guidance clarifies safety-reporting responsibilities and submission requirements for therapeutic products.
- **Part of:** [Healthcare](https://ik.sg/en/knowledge/topic/sgtopic.healthcare)
- **Primary domain:** healthcare

## Explore connections

- Articles: [HSA Post-marketing Vigilance Guidance 2026](https://ik.sg/en/knowledge/article/sgkb.healthcare.hsa-post-marketing-vigilance-guidance-2026)
- Topics: [Healthcare](https://ik.sg/en/knowledge/topic/sgtopic.healthcare)
- People & organisations: [HSA Post-marketing Vigilance Guidance Version 6](https://ik.sg/en/knowledge/entity/sg.guidance.hsa-post-marketing-vigilance-v6)
- Dated values: [HSA post-marketing vigilance guidance Version 6](https://ik.sg/en/knowledge/observation/sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision)

Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force. An expanding collection. Published counts show available knowledge, not complete coverage of Singapore.
